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ABSTRACT
Tumor-targeting contrast agents may facilitate resection of solid neoplasms 
during fluorescence-guided surgery. Preliminary safety and imaging efficacy of the 
near-infrared fluorescent probe DA364 were evaluated during surgical resection of 
spontaneous solid tumors in 24 dogs. Intra-operative imaging was performed in situ 
and on excised specimens to evaluate fluorescence intensities of tumor and adjacent 
tissues. After standard-of-care tumor resection, the wound bed was imaged again, 
and additional tissue was excised if residual fluorescence was detected.
DA364 was well tolerated after intravenous administration. The median tumor-
to-background ratio in situ for mammary tumors, mast cell tumors and sarcomas 
was 1.8 (range 1.2–3.9), 2.2 (range 1.0–5.6), and 4.2 (range 2.0–4.3), respectively. 
Qualitative intra-operative tumor identification was feasible in half of the cases. 
Remaining fluorescence was detected in four wound beds that contained residual 
disease, and in11 tumor-free wound beds, confirmed by histopathology.
Overall, DA364 did not raise safety concerns and showed accumulation in 
different types of spontaneous tumors, showing potential to pinpoint residual disease. 
Larger clinical trials are necessary to select accurate dosing and imaging protocols 
for specific indications to evaluate the sensitivity and specificity of the agent.
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INTRODUCTION
Despite many recent improvements in the medical 
treatment of cancer, surgery remains the most effective 
therapeutic strategy for the majority of patients with 
solid tumors [1]. Tissue palpation, visual inspection, and 
real-time frozen section analyses are commonly used by 
surgeons to identify tumor margins during resection, and 
to assess the presence of residual disease [1]. However, 
positive tumor margins after surgical resection are a 
common histopathological finding [2–4], which strongly 
increases the risk of cancer recurrence [5]. Thus, there is 
a high need for the implementation of new intra-operative 
methodologies that can provide accurate real-time 
tumor margin assessment to overcome the limitations of 
standard-of-care practice.
Fluorescence imaging is a safe and sensitive 
technique that may assist the surgeon by real-time 
delineation of tumor lesions during resection through 
visualization of specific fluorescent probes [6–8]. 
Particularly intra-operative near-infrared fluorescence 
(NIRF; 700–900 nm) imaging is currently being 
investigated using contrast agents that preferentially 
accumulate in tumor tissues, and that may be detected 
at greater depths and with higher image resolution than 
tracers emitting in the visible spectrum [8]. Indocyanine 
Green (ICG), the only NIRF agent currently approved for 
human use (i. e., angiography, lymph node (LN) mapping, 
liver function testing), has demonstrated limited sensitivity 
and specificity for intra-operative tumor identification in 
human and veterinary trials [9–11], due to its unspecific 
tumor accumulation mechanism. Novel contrast agents 
that recognize molecular epitopes overexpressed by tumor 
tissues (i. e., vascular endothelial growth factor, folate 
receptor, carcinoembryonic antigen) have shown safety 
and efficacy during clinical trials and hold great promise 
to be implemented in clinical practice [12–16].
In this study, preliminary safety and imaging 
efficacy of the NIRF agent DA364 were evaluated during 
resection of superficial solid tumors in canine patients. 
DA364 is composed of Cy5.5, a water-soluble cyanine 
dye (fluorescence quantum yield in serum: Cy5.5, 21%; 
ICG, 9%) [17, 18], and a cyclic Arg-Gly-Asp (RGD) 
peptidomimetic moiety, targeting integrins, which are 
the main cellular adhesion protein family implicated 
in nearly every step of tumor progression [19, 20]. 
It has previously been reported that DA364 has high 
affinity and specificity for integrin αvβ3 in vitro, and 
excellent imaging performance in vivo to detect tumor 
masses in rodent models of human cancers [21, 22]. 
In vitro evaluations were conducted to test the biological 
properties of the DA364 batch used for the canine 
trial. Based on the promising pre-clinical results, we 
hypothesize that DA364 accumulates in spontaneous 
tumors in dogs after intravenous (IV) administration, 
allowing intra-operative tumor detection and eradication 
of residual disease in the wound bed. Secondary 
objectives of the trial are: 1) to evaluate the probe’s tissue 
kinetics after injection, 2) to determine the optimal dose 
and time interval for tumor detection during surgery, and 




DA364 affinity to human αvβ3 integrin was 
evaluated in a solid phase binding assay via displacement 
of vitronectin, the physiological ligand of the receptor 
(Figure 1A). DA364 was able to compete for the binding 
to the target with single-digit nanomolar potency (IC50 
2.5 ± 0.2 nM), confirming the findings from previous 
batches of the product [21].
DA364 showed efficient internalization in human 
melanoma WM266 cells which overexpress the integrin 
receptor αvβ3 [23] (Figure 1B). The treatment with the 
competitor inhibited DA364 internalization in a dose-
dependent manner. An uptake inhibition of 85% was 
reached with a 50-fold concentration of the unconjugated 
cRGD peptidomimetic moiety.
Patient characteristics and study workflow
Between February 2016 and April 2017, 24 
dogs with 32 suspected superficial solid tumors were 
included in the clinical trial. Table 1 illustrates the 
general characteristics of the dogs, the tumor type (s) 
and respective trial data. The histopathological diagnosis 
of the major tumors revealed the presence of mast cell 
tumor (n = 9), mammary gland adenocarcinoma (n = 6), 
mammary gland adenoma (n = 2), vaginal leiomyosarcoma 
(n = 1), soft tissue sarcoma (n = 1), osteosarcoma (n = 1), 
cutaneous melanoma (n = 1), adenocarcinoma of the 
apocrine gland (n = 1), cysts of the mammary gland 
(n = 1), and lipoma (n = 1). Histopathological diagnosis of 
second smaller tumors that were identified during physical 
examination in eight dogs revealed the presence of an 
additional mammary gland adenoma (n = 5), mammary 
gland adenocarcinoma (n = 2), and pyogranulomatous 
dermatitis (n = 1). The cysts of the mammary gland and 
the pyogranulomatous dermatitis lesion were not included 
in any further analyses since both lesions do not have a 
neoplastic origin.
The study workflow (Figure 2) started with the IV 
administration of DA364 at various doses either 24 or 
48 h prior to surgery, followed by pre-operative imaging 
to assess tissue kinetics, then intra-operative imaging to 
evaluate fluorescence in tumors and surroundings, and 
post-operative imaging of resected specimen to verify the 
distribution of the fluorescent signal. Furthermore, the 
excised specimens were prepared for histopathological 
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assessment and for proteomic analyses to evaluate the 
expression of the integrin receptors.
Pre-operative imaging
No adverse effects were observed after IV 
administration of DA364. All patients were clinically 
stable; heart rate, respiratory rate and systolic blood 
pressure were within physiological ranges throughout the 
experiment. Reliable pre-operative kinetics were obtained 
in 12 tumors (5a, 6, 7, 9, 11, 14, 17, 18, 19a, 20a, 23, 
24). The selection of sufficient transcutaneous images of 
tumors was based on optimal image quality, which was 
highly affected by parameters such as the thickness and 
color of the skin, and transcutaneous fluorescence imaging 
feasibility, which was affected by the location of tumor. 
Analysis of the signal decay over time revealed a peak 
(Tmax) at 1.6 h post-injection (PI) and long-lasting tissue 
retention in the tumors (T1/2: 16.5 h).
Intra-operative imaging
The tumor was always removed with a certain 
margin of surrounding tissue, depending on the current 
recommendations for each tumor type, meaning no attempt 
was done to resect the tumor based on the intensity of the 
fluorescent signal. The dose of 0.06 mg/m2 was too low 
for intra-operative NIRF tumor detection. The dose of 0.6 
mg/m2 was sufficient to detect the tumor in situ, but the 
dose of 1.8 mg/m2 revealed sharper images, and therefore 
was selected as primary dose for the trial (Table 1). The 
dose of 3 mg/m2 did not improve image quality compared 
to the 1.8 mg/m2 dose whereas increased background 
fluorescence was observed.
The median tumor-to-background ratio (TBR) 
in situ for all mammary tumors, mast cell tumors and 
sarcomas was 1.8 (range 1.2–3.9), 2.2 (range 1.0–5.6), 
and 4.2 (range 2.0–4.3), respectively (Table 2, Figure 3). 
The analysis was not performed on six mammary tumors 
(two of which were adenocarcinomas) because the image 
quality was suboptimal, either due to the low dose of 
contrast administered or due to a tumor diameter of less 
than 5 mm. Although the intra-operative TBR was ≥ 1.0 
in all tumors (with the exception of the highly pigmented 
melanoma), the intra-operative qualitative evaluation 
showed a distinctive positive signal of the exposed 
lesion compared to adjacent tissues in only 15 out of 30 
tumors (Table 2). The lowest TBR in the tumor that was 
qualitatively identified was 1.2. Furthermore, there was 
no significant difference in TBRs between malignant 
tumors and benign lesions. Malignant mammary gland 
tumor patients imaged 48 h after administration showed 
subjectively lower background fluorescence than patients 
imaged after 24 h. However, delaying the surgery 
and acquisition to 48 h PI did not result in appreciable 
improvement of the in vivo TBR.
Complete resection of the tumor was deemed 
successful by standard-of-care evaluation in 27 out of 
30 lumps, and histopathology claimed negative surgical 
margins in 26 of those (Table 3). In two mast cell 
tumor cases (patients 11 and 22) and in the melanoma 
(patient 16), complete resection was not feasible due 
to the location (proximity of the eye and tarsus). As 
expected, tumor margins contained microscopic tumor 
remnants and fluorescence was detected in the wound 
bed (true positives). In one mast cell tumor (patient 10), 
a fluorescence signal was detected in the surgical bed, 
and histopathology showed that the tumor tissue reached 
until the section margins (true positive, undetected during 
surgery by standard-of-care examination). No remaining 
fluorescence was noted in 15 of the 26 histopathologically-
clean wound beds (true negatives, mostly mammary gland 
tumors). In the 11 remaining wound beds, fluorescence 
was noted but the biopsies did not contain tumor cells 
(false positives, mostly mast cell tumors and sarcomas) 
(Table 3).
Figure 1: In vitro analyses. (A) Representative sigmoid curve revealing single-digit nanomolar affinity of DA364 for the human αvβ3 
integrin receptor. (B) Dose-response inhibition of DA364 uptake in human melanoma WM266 cells by the unconjugated cRGD vector.
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1a: Adenoma T1N0M0 — Mammary 
gland1b: Adenoma T1N0M0 —
2 24 0.6 Jack Russell Terrier (Fn) 12.3 4.5 4
2a: Adenocarcinoma T2N1M0 III Mammary 
gland2b: Adenocarcinoma T1N0M0 I
3 24 1.8 Weimaraner (F) 6.3 40.0 6 Cysts — — Mammary gland
4 24 1.8 Malinois (Fn) 14.0 27.0 4
4a: Adenocarcinoma T3N1M0 III Mammary 
gland4b: Adenoma T1N0M0 —
5 24 1.8 Yorkshire Terrier (F) 13.9 3.5 3
5a: Leiomyosarcoma T3N0M0 — Vagina
Mammary 





10.0 23.0 4 Mast cell tumor Ia I Mid-femur
7 24 1.8 Labrador retriever (Fn) 8.2 34.5 5 Mast cell tumor Ia II
Ventral 
abdomen
8 24 1.8 Cross breed (M) 12.9 5.5 4 Mast cell tumor Ia II
Ventral 
abdomen
9 24 1.8 Maltese (Mn) 8.1 8.5 4 Mast cell tumor Ia II Left femur
10 24 1.8 Jack Russell Terrier (F) 5.7 8.5 6 Mast cell tumor IIb III
Left thoracic 
wall
11 24 1.8 Labrador retriever (F) 7.5 31.5 5 Mast cell tumor Ia II Tarsal region
12 24 3.0 Maltese (F) 6.3 6.5 4 Adenoma T1N0M0 — Mammary gland
13 24 3.0 Cross breed (F) 9.3 12.0 4
13a: SCC/
Adenocarcinoma T2N0M0 I Mammary gland
13b: Adenoma T1N0M0
14 24 1.8 German shepherd (Mn) 3.9 40.0 5 Soft tissue sarcoma T3N0M0 II Elbow region
15 24 1.8 Dobermann (Mn) 1.7 39.0 4 Osteosarcoma T2N0M0 —
Left thoracic 
wall
16 24 1.8 Shar-Pei (M) 12.4 24.0 5 Melanoma T2N0M0 High grade Left cheeck




the left anal 
sac
18 24 1.8 Labrador retriever (Fn) 9.5 41.0 6 Lipoma — —
Right 
inguinal area
19 48 1.8 Miniature Poodle (F) 8.4 4.0 4
19a: Adenocarcinoma T1N0M0 I Mammary 
gland19b: Adenoma T1N0M0 —
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Post-operative imaging
The fluorescence intensity in the center (tumor) 
and the outer edge (surgical margin) of the excised lumps 
was evaluated before formalin fixation (Figure 4). Eight 
samples were not included due to suboptimal image 
quality (Table 2). The median tumor-to-margin ratio 
(TMR) for all benign tumors and malignant tumors 
(melanoma not included) was 2.4 (range 1.6–3.4) and 3.4 
(range 1.2–14.4), respectively. Although subjectively a 
higher TMR was noticed in malignant tumors compared 
to benign lesions, statistical significance was not reached 
(p = 0.203). The median TMR ex vivo for all mammary 
tumors, mast cell tumors and sarcomas was 3.4 (range 
1.6–6.4), 2.6 (range 2.0–12.2), and 3.3 (range 1.2–5.4) 
respectively.
The signal-to-background ratio (SBR) in metastatic 
lymph nodes (3.28 ± 0.37) was significantly higher than 
in normal lymph nodes (1.58 ± 0.12) (t (4.83) = –4.32; 
p = 0.008) (Table 4). Qualitative evaluation of the excised 
LNs revealed a positive signal in all metastatic LN, 
while only two non-metastatic LNs showed detectable 
fluorescence.
Western blot and immunohistochemistry
The expression of the integrin subunits αV and β3 
in canine tumor extracts was not homogenous within the 
groups, and no relationship was found between integrin 
expression levels and tumor type, location or grade 
(Figure 5A). The expression of the αV subunit appeared 
greater than the β3 subunit in mammary gland tumors and 
20 48 1.8 Jack Russell Terrier (F) 12.8 7.0 5
20a: Adenocarcinoma T1N0M0 I Mammary 
gland20b: Adenocarcinoma T1N0M0 I
21 48 1.8 Labrador retriever (F) 9.9 37.0 5 Adenocarcinoma T2N0M0 I
Mammary 
gland
22 48 1.8 Labrador retriever (M) 11.1 41.0 6
22a: Mast cell tumor Ia III
Right tarsus
22b: PGD — —





10.3 35.0 5 Mast cell tumor IIa III Right tarsus
Abbreviations: BCS, body condition score; F, female; Fn, female neutered; M, male; Mn, male neutered; PGD, 
pyogranulomatous dermatitis; SCC, squamous cell carcinoma; TI, time interval.
Figure 2: Overview of the procedure to test DA364 as fluorescent contrast agent to highlight tumors during surgery. The 
workflow consists of the intravenous administration of DA364 24 h or 48 h prior to surgery (A), followed by pre-operative imaging (B, C: 
procedure and fluorescent image in panel respectively), intra-operative imaging (D, E: procedure and correspondent fluorescent image in 
panel respectively) and post-operative imaging (F, G: procedure and correspondent fluorescent image, visualized on screen, respectively). 
Excised tissues were sliced in 4 μm-thick sections and underwent tumor assessment by Hematoxylin and Eosin histopathology (H), and 
evaluation of the β3 integrin by immunohistochemistry (I).
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Table 2: Evaluation of fluorescence intensity in situ and on excised specimens
Dog Tumor type Dose (mg/m2) Intra-operative (in vivo) Post-operative (ex vivo)
Lesion Background TBR Qualitative evaluationa Center Margin TMR
1 1a: Adenoma 0.06 NAb NAb NAb — NAb NAb NAb
1b: Adenoma NAb NAb NAb — NAb NAb NAb
2 2a: Adenocarcinoma 0.6 40.7 22.3 1.8 — 144.1 79.0 1.8
2b: Adenocarcinoma NAb NAb NAb — NAb NAb NAb
4 4a: Adenocarcinoma 1.8 141.9 82.6 1.7 + 51.8 11.6 4.5
4b: Adenoma 172.8 107.1 1.6 + 102.6 30.6 3.4
5 5a: Leiomyosarcoma 1.8 49.2 24.4 2.0 — NAc NAc NAc
5b: Adenoma 115.9 36.7 3.2 + 100.9 52.5 1.9
6 Mast cell tumor 1.8 79.7 15.6 5.1 + 74.8 9.2 8.1
7 Mast cell tumor 1.8 35.4 6.3 5.6 + 51.3 25.9 2.0
8 Mast cell tumor 1.8 63.3 63.6 1.0 — 74.2 6.1 12.2
9 Mast cell tumor 1.8 24.4 11.1 2.2 + 57.0 26.2 2.2
10 Mast cell tumor 1.8 60.5 63.3 1.0 — NAd NAd NAd
11 Mast cell tumor 1.8 39.1 33.2 1.2 + 39.6 15.7 2.5
12 Adenoma 3.0 75.2 19.4 3.9 — 148.5 91.7 1.6
13 13a: SCC /
Adenocarcinoma
3.0 28.9 20.7 1.4 — 50.0 11.4 4.4
13b: Adenoma NAd NAd NAd — NAd NAd NAd
14 Soft tissue sarcoma 1.8 130.5 31.4 4.2 + 121.9 22.6 5.4
15 Osteosarcoma 1.8 96.4 22.7 4.3 + 51.7 43.2 1.2
16 Melanoma 1.8 13.0 78.8 0.2 — 1.1 19.8 0.1
17 Adenocarcinoma 1.8 99.8 31.4 3.2 + 142.8 9.9 14.4
18 Lipoma 1.8 61.7 14.4 4.3 + 78.5 27.9 2.8
19e 19a: Adenocarcinoma 1.8 113.0 30.2 3.7 + 166.2 26.1 6.4
19b: Adenoma NAd NAd NAd — NAd NAd NAd
20e 20a: Adenocarcinoma 1.8 51.6 28.7 1.8 — 57.6 29.1 2.0
20b: Adenocarcinoma NAd NAd NAd + NAd NAd NAd
21e Adenocarcinoma 1.8 20.6 16.6 1.2 — 61.2 18.0 3.4
22e Mast cell tumor 1.8 38.1 15.0 2.5 + 69.1 25.9 2.7
23e Mast cell tumor 1.8 42.9 17.0 2.5 — 38.6 10.9 3.5
24e Mast cell tumor 1.8 74.9 57.5 1.3 + 45.9 20.0 2.3
Fluorescence intensity is expressed as mean value of the region of interest. aQualitative evaluation indicates whether 
differentiation of the tumor was feasible during surgical resection of the tumor. bMeasurement of the fluorescent signal was 
not feasible because the administered dose was too low. cMeasurement of the ex vivo fluorescent signal was not feasible 
because no background region of interest could be selected since the resected specimen completely consisted of vaginal 
tumor. dMeasurement of the fluorescent signal was not performed because the tumor diameter was less than 5 mm. eDogs 
that received the probe 48 h prior to surgery. Abbreviations: NA, not available; SCC, squamous cell carcinoma; TBR, 
tumor-to-background ratio; TMR, tumor-to-margin ratio.
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sarcomas, while the opposite was recorded for mast cell 
tumors.
Qualitative immunohistochemical analyses 
performed for integrin β3 also showed variable expression 
and heterogeneous localization of the subunit in the tumor 
tissues (Figure 5B). Mammary gland tumors showed 
moderate expression in both tumor cells and stroma (i. 
e., blood vessels, fibroblasts, myoepithelial cells), while 
mast cell tumors showed mainly stromal staining. Variable 
staining intensity was detected in the examined LNs, with 
predominant stromal localization. Semi-quantitative 
evaluation by the intensity scoring (0/3) system in the 
tumoral cells revealed a low-to-moderate integrin β3 
expression in mammary tumors, a negligible expression 
in mast cell tumors and high expression in sarcomas 
(Table 5). Quantitative analysis of the total tumor stained 
area (tumor cells and stroma) revealed a moderate integrin 
β3 expression in mammary tumors, a low expression in 
mast cell tumors and high expression in sarcomas.
Given the low sample size and the high variability 
in integrin expression levels among the samples, no 
statistical evaluations were performed.
DISCUSSION
In this canine trial, preliminary safety and imaging 
efficacy of the fluorescent probe DA364 were assessed 
during fluorescence-guided surgery in dogs with 
spontaneous tumors, in combination with standard-of-
care practice. The contrast agent was well tolerated after 
IV injection at all doses tested, and the median intra-
operative TBR was > 1.8 for mammary tumors, mast cell 
tumors and sarcomas with TBRs up to 3.9, 5.6, and 4.3, 
respectively, reached in individual patients, suggesting 
overall good tumor delineation properties for DA364. 
Furthermore, DA364 pinpointed four wound beds that 
contained residual tumor cells (true positives), and 11 
fluorescence-positive beds which were tumor-free, 
confirmed by histopathology (false positives). Overall, 
the results of the trial suggest that fluorescence-guided 
surgery using DA364 is safe and feasible, the contrast 
agent accumulates in different tumor types, and may help 
to detect residual disease in the wound bed. However, the 
exploratory nature of the trial and the different variables 
and protocols tested mandate to consider such results as 
preliminary; further investigations will be necessary to 
fully gauge the performance of DA364, particularly its 
diagnostic accuracy.
The TBRs varied greatly between and within tumor 
types, as also observed in recent veterinary trials assessing 
another integrin-targeting probe [24, 25]. Interestingly, 
the melanoma showed the lowest TBR, probably because 
the dark pigmented lesion strongly absorbed the excitation 
light. Qualitative intra-operative fluorescence examination 
revealed sharp tumor identification only for half of the 
lesions. The discrepancy between the semi-quantitative 
(TBR, post-processing) and the qualitative (subjective 
visualization, real-time) outcome may be related to several 
factors. First, qualitative intra-operative discrimination of 
lesions with a modest TBR (1.1–1.5) may be suboptimal 
compared to lesions with a higher TBR. Secondly, the 
hand-held device used in the trial carries an inherent 
position variability towards the surgical field, and therefore 
tissue signal intensity and relative contrast may slightly 
differ between intra-operative examination (e. g., multiple 
positioning during surgery) and post-processing analyses 
conducted on a single image. Automatic thresholding 
algorithms embedded in the imaging system software 
may facilitate future real-time tumor delineation based on 
the TBR. The use of fixed-distance intra-operative camera 
systems with automatic thresholding algorithms may also 
help to overcome these shortcomings in future trials.
Figure 3: Intra-operative imaging. (A) Representative brightfield (left) and fluorescence (right, 40 ms exposure) images in situ of 
an adenocarcinoma 24 h after administration of DA364 (patient 17; 1.8 mg/m2). The asterisk denotes the mass, the dotted line denotes 
the tumor region of interest and the solid line denotes the background region of interest. (B) Evaluation of tumor-to-background ratios in 
different tumor types. Horizonal bars represent medians.
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Table 3: Intra-operative evaluation of the lesion by standard-of-care inspection and fluorescence in the wound bed
Tumor
Lump margin inspection 




in wound bed 
(samples)
Histopathologyc Description
1a: Adenoma Negative Negative Negative — —
1b: Adenoma Negative Negative Negative — —
2a: Adenocarcinoma Negative Negative Negative — —
2b: Adenocarcinoma Negative Negative Negative — —
4a: Adenocarcinoma Negative Negative Negative — —
4b: Adenoma Negative Negative Negative — —
5a: Leiomyosarcoma Negative Negative Positive (1) Negative Healthy vaginal wall
5b: Adenoma Negative Negative Negative — —
6: Mast cell tumor Negative Negative Positive (1)d Negative
Skin with minimal 
perivascular 
lymphocytic infiltrate
7: Mast cell tumor Negative Negative Positive (1) Negative Adipose and connective tissue
8: Mast cell tumor Negative Negative Positive (1) Negative Adipose tissue and skeletal muscle
9: Mast cell tumor Negative Negative Negative — —
10: Mast cell tumor Negative Positive Positive NAe NAe
11: Mast cell tumor Positive Positive Positive (1) Negative Adipose and connective tissue
12: Adenoma Negative Negative Positivef NAf NAf
13a: SCC /
Adenocarcinoma Negative Negative Positive (1) Negative Mammary gland
13b: Adenoma Negative Negative Positivef NAf NAf
14: Soft tissue sarcoma Negative Negative Positive (2) Negative Skeletal muscleNegative Normal tendon
15: Osteosarcoma Negative Negative Positive (2) Negative Collapsed lung lobeNegative Thickened pleura
16: Melanoma Positive Positive Positive (1) Negative Mucinous connective tissue
17: Adenocarcinoma Negative Negative Negative — —
18: Lipoma Negative Negative Negative — —
19a: Adenocarcinoma Negative Negative Negative — —
19b: Adenoma Negative Negative Negative — —
20a: Adenocarcinoma Negative Negative Negative — —
20b: Adenocarcinoma Negative Negative Negative — —
21: Adenocarcinoma Negative Negative Negative — —
22: Mast cell tumor Positive Positive Positive NAe NAe
23: Mast cell tumor Negative Negative Positive (1) Negative Normal skin
24: Mast cell tumor Negative Negative Positive (1) Negative Subcutis with large blood vessel
aPositive by standard-of-care assessment denotes incomplete resections of the lump or suspicion of contamination in the 
wound bed. bPositive by fluorescence imaging denotes the presence of a fluorescent signal in the resected sample. cPositive 
by pathology denotes the presence of tumor tissue. dFalse positive tissue removed adjacent to neoplastic tissue and not from 
the wound bed. eNo additional biopsy could be taken because of the anatomical location. fNo addititonal biopsy was taken 
because the high homogenous background was attributed to the high dose that these dogs received. Abbreviation: NA, not 
available.
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Two previous veterinary clinical trials described 
the use of an integrin-targeting probe containing a 
cyclodecapeptide scaffold with 4 c (RGDfK) motifs and 
a fluorescent dye (Angiostamp, Fluoptics, Grenoble, 
France), during fluorescence-guided surgical resection 
of tumors in cats and/or dogs using the Fluobeam system 
[24, 25]. In the first trial, 12 cats with fibrosarcoma 
underwent fluorescence-guided surgery [24], whereas in 
a second study only one cat with mammary gland tumors 
and three dogs with different tumor types (mammary 
gland (2) and/or ovarian (2) disseminated tumors) were 
enrolled [25]. Angiostamp showed good accumulation in 
the tumors and high intra-operative TBRs. As pointed out 
by the investigators, the large tumor-free margin routinely 
taken in fibrosarcoma cases often emitted a moderate 
fluorescent signal due to peri-tumoral inflammation, 
potentially hampering distinct delineation of the tumor 
itself [24]. A direct comparison between canine and feline 
studies using Angiostamp for NIRF imaging and our trial 
using DA364 is challenging. Most important confounding 
factors include the different patient enrolment and tumor 
characteristics, the different spectral properties and dosing 
of the contrast agents, and technical variables related to the 
camera systems [26]. Another relevant parameter that may 
strongly affect the study outcome, particularly the TBR, is 
the definition of the ROIs. For the intra-operative images, 
we selected as “background” a region as close as possible 
to the primary tumor, either adjacent or even underneath 
when the tumor was flipped over. It is not clear how the 
background areas were selected in the Angiostamp studies 
to derive the TBR, and whether the ratiometric analysis 
was performed using an image containing both tumor and 
background ROIs (as in our study), or different images. A 
standardized method to select ROIs in fluorescence-guided 
surgery is necessary to perform an unbiased evaluation of 
the TBR [27]. The results of the Angiostamp studies and 
the present trial suggest that integrin-targeting approaches 
using small fluorescent contrast agents are capable to 
detect tumor lesions during surgical resection and to assist 
the surgeon beyond standard-of-care.
During the trial, different doses of the contrast 
agent were evaluated. The dose of 1.8 mg/m2 (0.05 mg/kg 
human estimated dose after allometric scaling) yielded the 
most optimal TBR for intra-operative detection of tumor 
lesions. At lower doses (0.06 – 0.6 mg/m2), the imaging 
performance of the contrast agent was suboptimal, 
probably due to low accumulation and low fluorescent 
signal detected by the camera system used in this trial 
which is known to underperform at low concentrations 
[26]. We believe that the use of a fluorescence camera 
with higher sensitivity may allow reduction of the drug 
dosage. Two imaging time-points (24 and 48 h PI) were 
evaluated to assess the relationship between background 
signal reduction and tumor contrast generation. Delaying 
the surgery till 48 h PI did not improve the TBR. After 
post hoc analysis of the signal decay, the T1/2 of DA364 
retention in the tissues appeared to be 16.5 h PI. Therefore, 
future studies should investigate whether a decrease 
in time interval between injection and imaging would 
potentially result in improved in situ TBR and ex vivo 
TMR. Likely, the most appropriate protocol (dose and 
imaging time-point) will depend on the type of tumor, 
and future trials will be necessary to define the optimal 
protocol for a selected indication.
Besides intra-operative tumor identification, 
detection of residual disease is probably the other main 
unmet need that fluorescence-guided surgery may 
address, to reduce cancer recurrences due to positive 
margins, to prevent additional surgeries, and to improve 
the quality of life and survival of the patients. Indeed, 
the detection of residual disease is a primary endpoint 
for confirmatory human trials in fluorescence-guided 
Figure 4: Post-operative imaging. (A) Representative brightfield (left) and fluorescence (right, 40 ms exposure) images of an excised 
mammary gland adenocarcinoma 48 h after administration of DA364 (patient 19; 1.8 mg/m2). The asterisk and the pins denote the mass, 
the dotted line denotes the tumor region of interest (ROI), the inner solid line the background ROI, and the outer solid line the margin ROI. 
(B) Evaluation of tumor-to-margin ratios in different tumor types. Horizonal bars represent medians.
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surgery (e. g., NCT03180307 for ovarian cancer, 
NCT03686215 for breast cancer). NIRF imaging using 
DA364 highlighted four wound beds containing residual 
tumor lesions. Particularly in one dog in this trial, the 
surgeon considered the wound bed to be clean based on 
standard-of-care inspection, but fluorescence was noted 
in the caudal wound bed and histopathology confirmed 
positive margins. In this case, the use of DA364 may 
have prevented the dog a second surgery. The four true 
positive wound beds detected in this canine trial suggest 
positive performance of DA364 for residual disease 
identification during surgery. On the other hand, 11 wound 
beds emitting false positive fluorescence were detected, 
probably due to non-specific accumulation of DA364 in 
connective and lipid tissues, or binding of the fluorescent 
probe to the activated endothelial cells, present in the 
tumor and peri-tumoral environment [19]. In those dogs, 
additional biopsies were taken. Although no complications 
were associated with these additional resections, longer 
anaesthesia and surgery times were recorded. Of note, the 
vast majority of false positives tissues were removed in 
mast cell tumor and sarcoma cases, while only one false 
positive sample was obtained after mastectomy (in a dog 
receiving the highest tested dose). The rate of false and true 
Table 4: Quantitative and qualitative evaluation of fluorescence in excised regional lymph nodes (LN)






1 Superficial inguinal 41.8 38.5 1.09 — Negative
2 Superficial inguinal 12.3 4.4 2.80 + Positive
3 Superficial inguinal 24.6 16.2 1.52 — Negative
4 Superficial inguinal 21.6 6.0 3.60 + Positive
10 Axillary 26.1 6.2 4.21 ++ Positive
12 Superficial inguinal 59.3 39.6 1.50 — Negative
13 Superficial inguinal 17.5 8.1 2.16 + Negative
14 Axillary 12.8 8.3 1.54 — Negative
19 Superficial inguinal 21.7 13.9 1.56 + Negative
21 Superficial inguinal 7.2 4.2 1.71 — Negative
22 Popliteal 30.5 8.2 3.72 + Positive
24 Popliteal 36.7 17.6 2.09 + Positive
aSignal-to-background ratios obtained in ex vivo LN cut in half before formalin fixation at 40 ms exposure vs. adjacent fat 
tissue (background). bQualitative evaluation denotes whether detection of a fluorescent signal was feasible in the LNs ex 
vivo before fixation. cHistopathological analysis confirmed the presence (positive) or absence (negative) of neoplastic cells 
in the LN. Abbreviation: SBR, signal-to-background ratio.
Figure 5: Ex vivo evaluation of integrins expression. (A) Western blot analysis of integrin receptor subunits expression per tumor 
type. Black circles, malignant tumors; grey circles, benign tumors. Horizonal bars represent medians. (B) Representative image of β3 
integrin immunostaining on a mammary gland adenocarcinoma showing tumor cell and stromal staining (brown, β3 integrin positive stain; 
cell nuclei are stained with Hematoxylin in blue). Scale bar, 100 microns.
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positives is a very important parameter for a diagnostic 
agent, particularly when considering applications 
such as breast-conserving surgeries. For this trial, we 
documented the results case by case, listing all additional 
tissue samples that were removed after standard-of-care 
resection. At the same time, we would like to stress that 
these results should be considered preliminary, given the 
exploratory nature of the trial and the variety of variables 
tested (i. e., different doses, different injection-to-imaging 
time-points, highly heterogeneous patient population and 
tumor characteristics). Further trials using DA364 will be 
necessary to assess the diagnostic accuracy of the agent in 
an optimal protocol and applied to a selected indication, 
using a fluorescence camera with high performance.
Fluorescence evaluation of resected specimen 
showed higher fluorescence signal in the center of 
lesions compared to the safety margin left by the surgeon, 
confirming the accumulation of DA364 in the lesion 
detected intra-operatively. Ex vivo ratiometric evaluation 
of the fluorescence in resected specimens revealed overall 
higher TMRs than intra-operative TBRs. This is probably 
because for ex vivo imaging, the specimen was cut in half 
before imaging, exposing deep fluorescent portions of the 
sample that may have been masked in vivo by overlying 
layers of tissue, and not readily detected by the NIRF 
camera which has limited penetration depth capabilities.
NIRF imaging using DA364 also showed 
preliminary efficacy for detection of metastasis in a 
small number of regional LNs. Intra-operative detection 
of a fluorescent LN might provide crucial additional 
information during surgery [28]. In this trial, the SBR of 
resected metastatic LNs was significantly higher than the 
SBR of non-metastatic LNs. However, in situ evaluation 
of LN fluorescence was challenging, probably due to the 
anatomical location (embedded in fat) of the nodes and the 
limited penetration depth of the technology [7]. Further 
evaluations will be necessary to confirm these preliminary 
findings on a larger population.
The presence of the integrin receptors was 
evaluated on resected specimen. Immunohistochemical 
evaluation of anti-β3 showed positive staining in sarcoma 
and mammary tumor cells, but not in mast tumor cells. 
Table 5: Semi-quantitative (score) and quantitative (area) evaluation of anti-b3 integrin staining in tumor samples
Dog Tumor type IHC (b3 integrin in tumor cells, score 0/3)
IHC (b3 integrin positive area tumor 
area)
2 2a: Adenocarcinoma 1/3 25%
2b: Adenocarcinoma 2/3 4%
4 4a: Adenocarcinoma — —
4b: Adenoma 0.5/3 3%
5 5a: Leiomyosarcoma 3/3 53%
5b: Adenoma 1/3 13%
6 Mast cell tumor 0/3 1%
7 Mast cell tumor 0/3 1%
8 Mast cell tumor 0/3 1%
9 Mast cell tumor 0/3 2%
11 Mast cell tumor 0/3 2%
13 13a: Adenocarcinoma 0.5/3 13%
14 Soft tissue sarcoma 2/3 13%
15 Osteosarcoma 3/3 48%
16 Melanoma 1/3 —
17 Adenocarcinoma 0.5-1/3 11%
18 Lipoma 0/3 1%
19 19a: Adenocarcinoma 2/3 16%
19b: Adenoma 1/3 12%
20 20a: Adenocarcinoma 0.5/3 —
20b: Adenocarcinoma — —
21 Adenocarcinoma 1-2/3 11%
22 Mast cell tumor 0/3 2%
23 Mast cell tumor 0/3 4%
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Presence of the β3 receptor subunit was found in greater 
but variable extent in the tumor stroma, suggesting the 
presence of neoangiogenesis or integrin-expressing 
tumor-associated cells. In mast cell tumors, the expression 
of β3 is likely associated with the presence of tumor 
vascularization, since no staining was found in tumor 
cells. Western blot analyses conducted on punch biopsies 
revealed the presence of β3 protein in all tumor types, 
with heterogeneous expression. β3 protein is a reliable 
indicator of the αvβ3 integrin receptor, since it only 
forms dimers with the αV subunit on tumor epithelial 
and stromal cells (of note, αIIbβ3 is only found on 
platelets), while aV protein may also assemble with other 
β subunits. No apparent correlation was found between 
the presence of β3 integrin and DA364 signal in tumors. 
This is probably due to several factors, including the 
small amount of tissue submitted for target expression 
analyses (i. e., punch biopsy and thin histological slice) 
which may not be representative for the whole tumor, 
but also the contribution of different mechanisms to the 
tumor accumulation properties of the contrast agent, such 
as passive diffusion through leaky vessels in addition to 
target-depended uptake. Furthermore, since the RGD-
binding moiety can recognize different integrin receptor 
dimers other than αvβ3, an evaluation conducted only 
on the β3 protein may be misleading and limitative to 
address the presence of the biomarkers pool potentially 
recognized by the molecular imaging agent. Here, we 
evaluated the expression of the αV subunit by western 
blot as surrogate for the αV integrin receptors pool. 
Similar to the variable presence of integrin subunit β3, a 
heterogeneous expression of the integrin αV subunit was 
found in all tumor types. Nonetheless, we acknowledge 
that assessing the expression of the β3 and αV subunits may 
be suboptimal, affected by the presence of cytoplasmic 
fractions not relevant for membrane targeted uptake, 
and not entirely representative of the final heterodimers 
population. Unfortunately, in this study the evaluation 
of the intact dimers was not possible by western blot 
because of the separation in monomers during tissue 
processing, and the lack of monoclonal antibodies for 
immunohistochemistry validated on canine tissue. This 
should not be a limiting factor for human translation since 
αvβ3, αvβ5 and αVβ6 antibodies are available and validated 
for formalin-fixed paraffin-embedded human tissues [29].
We acknowledge some limitations of this study. 
First, a heterogenous patient population was enrolled 
with a relatively small number of cases within each 
tumor type. In veterinary medicine, it is common to 
pre-operatively assess the nature of the tumor, based on 
fine-needle-aspirates only. Cytology minimizes the cost 
for the owner and avoids anaesthesia, required for pre-
operative core biopsies, but is less accurate than histology. 
Consequently, post-operative histopathology might 
identify another tumor type than expected based on pre-
operative cytology, which was the case for some tumors 
enrolled in this trial. Second, the hand-held system used in 
the trial suffers from inherent positioning variability, field 
inhomogeneity and limited sensitivity. Some samples were 
not evaluated because of suboptimal image quality. Image 
quality would benefit from using a fixed-position camera 
with high sensitivity. Furthermore, the majority of tumors 
for which evaluation of the signal was not feasible were 
additional tumors that were diagnosed during physical 
examination and that had a small diameter (less than 5 
mm). Measurement of the fluorescence in those samples 
appeared not feasible. Finally, no parallel control group 
(e. g., standard-of-care without fluorescence imaging) 
was included. A control arm may allow randomization 
and masking, with both arms receiving the contrast agent 
(to assess safety) and standard-of-care surgery, but only 
one cohort of patients submitted to fluorescence-guided 
surgery. This study design may allow to truly assess the 
added value of fluorescence-guided surgery by evaluating 
the number of fluorescent residual lesions identified in the 




The fluorescent contrast agent DA364 (Bracco 
Imaging SpA, Italy) was synthetized as previously 
reported [21]. The empirical formula of DA364 is 
C63H77N11O20S4 and the molecular mass is 1436.60 g/
mol. DA364 has excitation/emission maxima at 676/696 
nm and very high brightness (molar extinction coefficient: 
275,000 L * mol-1 * cm-1) in phosphate buffer saline (pH 
7.4) (unpublished data).
In vitro analyses
Receptor binding assay and cell uptake blocking 
experiments were performed as previously described 
[21]. A 96‐well microtiter plate was coated overnight 
at 4° C with 1 μg/mL recombinant human αvβ3 integrin 
(Merck-Millipore, Darmstadt, Germany) in coating buffer 
(20 mM Tris HCl pH 7.4; 150 mM NaCl; 1 mM MnCl2; 
0.5 mM MgCl2; 2 mM CaCl2). After coating, the plate was 
rinsed in washing buffer, then incubated in blocking buffer 
(3% BSA in coating buffer) for 2 h, under shaking and 
at room temperature (RT). The plate was then rinsed in 
washing buffer and incubated with the testing compounds 
in the presence of 1 μg/mL biotinylated vitronectin 
(Molecular Innovation), for 3 h at RT. The plate was then 
rinsed again and incubated in streptavidin–HorseRadish 
Peroxidase solution (GE Healthcare, Chicago, USA) 
for 1 h at RT. After rinsing, the plate was incubated in 
TetraMethylBenzidine (Sigma-Aldrich, Darmstadt, 
Germany) solution for 5 min and the colorimetric 
reaction was stopped by adding 2 M sulfuric acid. The 
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evaluation of the half-maximal inhibitory concentration 
(IC50) for the testing compounds was calculated by 
measuring the competitor (biotinylated vitronectin) by 
reading the absorbance at 450 nm (Optical Density). 
All samples were analyzed in triplicate and each assay 
was performed 3 times. IC50-values were determined by 
nonlinear regression analysis of the slope. For cell uptake 
experiments, WM266 human melanoma cells were seeded 
on 24-wells plate over 24 h, and then incubated with 
1 µM of DA364 in fresh serum-free medium in presence 
or absence of unconjugated cRGD peptidomimetic 
(1, 5, 10, 50, 100 µM) for 20 min at 37° C. At the end of 
incubations, the cells were rinsed with cold PBS, collected 
and suspended in PBS. Cells were gated according to 
their light‐scattering properties to exclude cell debris 
and cell fluorescence was analyzed (minimum 20000 
events/sample) using Accuri C6 flow cytometer (Becton 
Dickinson, San Jose, USA). Excitation laser was set at 
640 nm and the fluorescence emission was collected with 
670 nm long pass filter. Three independent experiments 
were performed in triplicates. Results were expressed as 
percentage of the maximum uptake (i. e., cells incubated 
with DA364 in absence of unlabeled cRGD).
Patient enrollment
Twenty-four client-owned dogs with a tentative 
diagnosis of surgically manageable solid neoplasia based 
on localization and palpation (mammary gland tumor) or 
cytology (melanoma, (sub) cutaneous mast cell tumor, 
(adeno) carcinoma or sarcoma) were considered for 
enrolment in the trial. The local research ethical committee 
granted ethical approval for this clinical trial (Institutional 
Animal Care and Use Committee; EC2015/124). 
Additionally, this project received approval of the 
deontological committee of the Federal Public Service 
Health, Food Chain Safety and Environment for the 
enrolment of non-purpose-bred dogs. All owners signed 
an informed consent form. Pre-surgical staging according 
to the World Health Organization (WHO) guidelines 
was completed the day of diagnosis; a thorough physical 
examination, complete routine blood analysis (hematology 
and biochemistry), urinalysis, thoracic radiographs (3 
orthogonal projections), and/or abdominal ultrasound with 
guided fine-needle aspiration of regional superficial LNs 
(if applicable) were performed. Dogs were eligible when 
no distant metastases were detected and when there were 
no indications for kidney and/or hepatic impairment based 
on blood and urinalysis and medical imaging.
DA364 administration
Prior to administration of the contrast agent, heart 
rate, respiratory rate, and systolic blood pressure were 
determined. In dogs diagnosed with a mast cell tumor, 
0.2 mg/kg promethazine (Phenergan, Hikma, Hoorn, The 
Netherlands) was administered intramuscularly (IM) to 
prevent potential histamine release. Dogs received either 
0.06 mg/m2, 0.6 mg/m2, 1.8 mg/m2, or 3 mg/m2 as an IV 
bolus of undiluted DA364 via a cephalic vein (Table 1). 
The dose of DA364 was calculated based on the Body 
Surface Area. Before and after the administration of the 
contrast agent, the catheter was flushed with 2 mL sodium 
chloride (NaCl 0.9%, B. Braun Melsungen AF, Germany) 
to ensure patency, and then a mandarin was inserted until 
anesthetic induction at the time of surgery.
Fluorescence imaging
Near-infrared fluorescence imaging was performed 
using the clinical Fluobeam 700® (Fluoptics, Grenoble, 
France), a commercially available hand-held system which 
consists of a control unit with a laser source emitting at 
680 nm, apart from an optical head with a charge-coupled 
device camera and white light emitting diodes for the 
illumination of the field of view, equipped with a long-
pass emission filter (>700 nm). The optical head was 
fixed in a custom-made tripod, ensuring a fixed working 
distance of 17 cm to reach a 6-cm spot diameter at the 
field of view during pre- and postoperative imaging. For 
intra-operative imaging, the optical head was hand held 
and a similar working distance was pursued.
Pre-operative imaging
The probe was administered 24 or 48 h prior to 
surgery. Transcutaneous imaging was performed 5, 10, 
30 and 60 min PI and then hourly until 6 h and 24 h PI 
in dogs that received the probe 24 h prior to surgery. 
Transcutaneous imaging was performed 5, 10, 30, 60 min, 
24 h and 48 h PI in dogs that received the probe 48 h prior 
to surgery. Dogs were hospitalized and vital parameters 
(heart rate, respiratory rate and systolic blood pressure) 
were assessed at predetermined intervals to screen for 
adverse effects until surgery. Acquired images were 
analyzed using a commercial image analysis tool (ImageJ 
v1.52). Regions of interest (ROIs) were drawn on tumor 
tissues based on the location of the mass identified during 
visual inspection and palpation, and the signal obtained 
was used to assess the tissue kinetics of the contrast agent.
Intra-operative imaging
The Fluobeam 700® was covered with a dedicated 
single-use sterile cover. In dogs diagnosed with a mast 
cell tumor, administration of promethazine was repeated 
immediately prior to anaesthetic induction. The choice 
of general anesthesia and analgesia protocols was based 
on the attending anesthesiologist’s preference. Surgical 
preparation was routinely performed. Surgical approaches 
were identical to those routinely used in dogs under white 
light with routine surgical margins and en bloc regional 
LN resection (if applicable). The surgery was briefly 
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interrupted at several occasions to acquire images and 
videos while the operation and ambient lights were turned 
down. Images of the surgical field were obtained before 
the surgical incision and once the tumor was partially 
detached from the surrounding tissue and folded over so 
that the deep border could be imaged in situ at the same 
time as the wound bed. After removal of the tumor, the 
wound bed was evaluated by NIRF imaging to assess 
if there was residual fluorescent signal. Remaining 
fluorescent tissue was removed or, if this fluorescent 
tissue was outsized or removal deemed delicate, a biopsy 
was taken; those samples were identified as “fluorescence 
positive” and processed separately. A small tissue sample 
of tumor tissue was immediately frozen at –80° C for 
western blot analysis. When all images and samples were 
obtained, the surgical wound was closed routinely and the 
dog was recovered from anesthesia. Images were analyzed 
using a commercial image analysis tool (ImageJ v1.52) 
to assess the fluorescent signal in tumor and background 
tissue. The background tissue was defined as a putative 
healthy tissue close to the tumor, either the wound bed 
or an adjacent tissue in case tumor and bed were not in 
the same image. The fluorescence signal intensity from 
the tumor and background tissue was obtained by drawing 
ROIs on the tissue flap during removal, and the ratio was 
used to calculate the TBR (Figure 3).
Post-operative imaging
Images of the excised tissue samples were acquired 
immediately after surgical removal of the tumor. Tumor 
and surrounding tissue, fluorescence-positive samples of 
the wound bed, and the LNs (if applicable) were imaged 
on a black surface. The tumor itself was then cut in half 
along its longitudinal axis and imaged with the cut planes 
facing upwards. Regions of interest were drawn on tumor 
and safety margins on the acquired ex vivo images using 
a commercial image analysis tool (ImageJ v1.52), and 
the fluorescent signal obtained was used to calculate the 
TMR. Regions of interest were also drawn on the resected 
LNs and adjacent fat tissue to derive the SBR. All samples 
were then fixed in abundant amounts of 10% formalin 
(CellStor Pot, CellPath, Wales, United Kingdom) for 24 h. 
Subsequently, half the tumor was further divided in slices 
of 3-5 mm thickness. A slice (tumor and surroundings) with 
maximal fluorescence was trimmed to fit into a histology 
cassette (UniSette, Sacramento, US), the most fluorescent 
side facing down, and re-immersed in a formalin container.
Western blot
Tissue samples were homogenized by Precellys 
homogenizer directly in Lysis buffer (50 mM Tris-HCl pH 8; 
150 mM NaCl; 1 mM EDTA; 100 mM NaF; 10% glycerol; 
1 mM MgCl2; 1% TritonX-100; Protease Inhibitors), and 
put in ice for 20 min. Some samples, particularly those 
difficult to homogenize, were subsequently pulverized using 
mortar and pestle in presence of liquid nitrogen. The final 
extract was sonicated for 15 sec and centrifuged at 14000 g 
at 4° C for 15 min. The protein content of the supernatant 
was quantified by the bicinchoninic acid assay method: 
50 µg of the total extract of each sample was loaded in a 
10% polyacrylamide gel and electrophoresis was performed 
to separate the proteins by their molecular weight in 
denaturing conditions (20% Sodium Dodecyl Sulfate). 
Proteins were then transferred onto a Polyvinylidene 
difluoride membrane and subsequently blotted with the 
antibodies anti-integrin subunit β3 (#BK13166, Cell 
Signaling, Leiden, Netherlands) and anti-integrin subunit 
αV (#Ab179475, Abcam, Cambridge, United Kingdom) to 
evaluate protein expression, and with the antibody anti-
actin (#BK4970, Cell Signaling, Leiden, Netherlands), to 
allow signal normalization on the loaded proteins. Specific 
signal was visualized as a single or multiple band by an 
electrochemiluminescence detection method. The images of 
the blotted membrane were acquired by a ChemiDoc MP 
Imaging system and the area of the bands relative to the β3 
expression levels were quantified with the software Image 
Lab v.4.1. The western blot analysis was repeated at least 
three times for all dog samples.
Histopathology
All formalin-fixed tissues were further trimmed, 
placed in cassettes and subjected to standard dehydration 
procedure followed by embedding in paraffin 
(60–65° C). Four µm-thick slices were cut from the 
paraffin blocks by a microtome. A representative slice 
of each block was routinely stained using hematoxylin 
and eosin. Histopathological evaluation was executed by 
a board-certified veterinary pathologist. Fluorescence-
positive tissue samples of the wound bed and the LNs 
(if applicable) were screened for the presence of tumor 
cells. The guidelines that the board-certified pathologist 
used to evaluate the tumor margins are based on the 
published guidelines by Kamstock and colleagues [30]. 
Samples containing (sub) cutaneous tumours (mast cell 
tumours) or sarcomas underwent cross-sectioning. In case 
of mammary gland tumours, each mammary gland was 
sampled as well as the lateral margins and the regional 
LNs. (Oral) melanomas also underwent cross-sectioning.
Immunohistochemistry
Tissue immunostaining was performed using an 
anti-β3 integrin antibody (monoclonal rabbit anti-integrin 
β3 antibody, clone EPR2417Y, #ab75872, Abcam, 
Cambridge, United Kingdom) and, as control, an anti-
IgG antibody with matching concentration (rabbit IgG 
isotype control antibodies, #3900, Cell signaling, Leiden, 
Netherlands). Serial sections were stained using routine 
hematoxylin and eosin for morphology reference. The 
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expression of β3 integrin in tumor cells and stromal 
tissues was assessed via qualitative, semi-quantitative 
and quantitative evaluations. Qualitative evaluation was 
done based on the description of the localization of the 
labelling (tissue, structures, cell types). The expression 
of β3 integrin in tumor cells was semi-quantified with 
a 4-tiered score (0: rare or none; 1: <30% of positive 
tumors cells; 2: 30% to 65% of positive tumor cells; 3: 
>65% of positive tumor cells). This visual evaluation 
assessed the labelling in the tumor cells only (stroma not 
included). A quantitative evaluation of the surface with 
IHC staining in selected tumor areas was achieved using 
HaloTM software (IndicaLabs, Albuquerque, NM). The 
selected tumor regions were chosen as large as possible, 
avoiding areas with artifacts (tissue folds, non-specific 
staining). The results were expressed as a percentage of 
stained areas per selected tumor surface. This represented 
an evaluation of the labelling in the tumor cells and in the 
stroma.
Statistics
Normality was confirmed for the in vivo TBR 
obtained in benign and malignant tumors, and ex vivo 
STB obtained in removed LNs (Kolmogorov-Smirnov 
test and Shapiro-Wilk test). Statistical differences between 
the TBR of malignant versus benign tumors, the TBR of 
malignant tumors in patients that received the product at 
24 h vs 48 h prior to surgery, and STBs in normal versus 
metastatic LNs were evaluated using the independent 
t-test. A p-value < 0.05 was considered significant. 
Normality was not confirmed for the ex vivo TMR values 
in benign and malignant tumors nor for the individual 
tumor types (mammary tumors, mast cell tumors and 
sarcomas). Statistical differences between the TMR of 
malignant versus benign tumors were evaluated using the 
Mann–Whitney U test. A p-value of < 0.05 was considered 
significant.
CONCLUSIONS
The integrin-targeting fluorescent probe DA364 
did not raise safety concerns and showed accumulation 
in different types of spontaneous tumors. Fluorescence-
guided surgery using DA364 is feasible, and may facilitate 
the delineation of primary lesions and the identification 
of residual disease missed by standard-of-care inspection. 
Larger clinical trials based a uniform patient population, 
a sensitive imaging system, and a specific dosing and 
imaging protocol are necessary to allow evaluation of 
sensitivity and specificity of the novel contrast agent.
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